Pharmacotherapeutics Of Schizophrenia, Australia

Main Category: Schizophrenia
Article Date: 07 Sep 2009 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Schizophrenia is one of the more costly diseases to manage in OECD countries and affects up to 1 per cent of the world's population.

And as a chronic and often severe neurodevelopmental disorder it accrues neurobiological, social and psychological deficits, and results in premature death after years of disability.

A special presentation at this year's Pharmacy Australia Congress will examine up-todate thinking regarding the targets of pharmacotherapuetic intervention, within the multidimensional incomplete recovery framework.

Presented by Professor Tim Lambert, Professor of Psychological Medicine at Concord Clinical School at The University of Sydney in Australia, the presentation will also delve into the forms of current therapy (drug classes, putative mechanisms), developments in formulation (oral, dissolvable, LAIs), and briefly present elements of future pharmacotherapeutic treatments that are in development.

Professor Lambert will conclude by presenting the salient clinical issues surrounding real world clinical effectiveness.

The presentation is one of the many topical issues being examined at PAC, the preeminent pharmacy event of the year being held at the Sydney Hilton from 15-18 October under the primary theme of Securing Your Practice Advantage.

Professor Lambert joins national and international speakers of note who have accepted invitations to present at PAC.

Professor Lambert is one of the leading specialists in his field and on top of his position at the University of South Australia, he is Head of Schizophrenia Treatment and Outcomes Research at the Brain & Mind Research Institute in Sydney.

In addition, he fulfils clinical duties for the SSWAHS in Sydney as Director of the Centre of Excellence in Relapse Prevention in Psychosis (CERP), and at the Concord Centre for Cardiometabolic Health in Psychosis (ccCHIP).

He has been a principal in the development of a number of clinical practice guidelines, algorithms, and consensus documents. Currently, he is chairing the consensus development group for treatment-resistant schizophrenia.

He is a member of a number of international and national advisory groups concerned with antipsychotic treatments.

Full details of PAC can be found at http://www.pac2009.com.au

Source
Pharmaceutical Society of Australia